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Bern, SwitzerlandBackground & Aims: Late-onset symptoms of urea-cycle disor- absence of liver dysfunction. Awareness of this important associ-
der may lead to a life-threatening disease which is often unde-
tected. We report the clinical and metabolic manifestations of
acute hyperammonemic encephalopathy in a 47-year-old asymp-
tomatic man with ornithine transcarbamylase (OTC) deﬁciency.
The hyperammonemic encephalopathy was unmasked by a
high-protein Atkins diet.
Methods: Genetic analysis of the patient’s family, 89 unrelated
Ashkenazi Jewish and 50 unrelated Europeans subjects was per-
formed using polymerase chain reaction ampliﬁcation and DNA
sequencing of the OTC gene.
Results: Treatment with hemodialysis, provision of adequate cal-
ories to prevent catabolism, and protein elimination for 24 h fol-
lowed by protein restriction and ammonia scavenging
medications effectively lowered the patient’s plasma ammonia
level and resulted in full recovery. Genetic analysis of the OTC
gene revealed a novel hemizygous missense mutation in exon 5
(c.477T>G), leading to an isoleucine-to-methionine substitution
in codon 159 (Ile159Met). Further genetic analysis of the
patient’s family yielded the mutation in many of them, although
ﬁndings were negative in 89 unrelated Ashkenazi Jewish and 50
unrelated Europeans subjects.
Conclusions: This is the ﬁrst reported case of an adult urea-cycle
defect unmasked by the Atkins diet. Measurements of serum
ammonia level must be part of the basic work-up in all patients
presenting with encephalopathy of unknown origin even in theJournal of Hepatology 20
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ment. Correct diagnosis is also important to prevent future
recurrences and to provide genetic counselling for family
members.
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Urea-cycle disorders are inborn errors of metabolism resulting
from partial or complete inactivity of any of the ﬁve enzymes
in the urea cycle, which is responsible for eliminating nitroge-
nous waste. The nitrogen accumulates in the form of ammonia,
and if left untreated, leads to episodic, life-threatening hyperam-
monemia encephalopathy, seizures, and coma [1,2]. The disor-
ders do not cause liver disease, although the consequences of
hyperammonemia resemble those in patients with hepatic failure
[1].
The most common urea-cycle disorder is ornithine transcar-
bamylase (OTC) deﬁciency, which has an estimated prevalence
of 1 in 14,000 and is transmitted as an X-linked trait [1,3,4].
The phenotype is extremely heterogeneous, ranging from com-
plete absence of symptoms in hemizygous males who might
become symptomatic only much later in life [5–7] to acute neo-
natal hyperammonemic coma. Researchers hypothesize that
complete OCT deﬁciency is associated with neonatal disease
and partial deﬁciency, with late-onset presentations. More than
80% of heterozygous females are asymptomatic; in the remain-
der, the clinical severity of the disease is similar to that in males
with partial deﬁciencies [3,4].
The clinical signs and symptoms of OTC deﬁciency are caused
by the toxic effects of hyperammonemia on the brain. They
include lethargy, vomiting, behavioral and neurological abnor-10 vol. 52 j 292–295
Table 1. Baseline laboratory ﬁndings.
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malities, and in severe cases, coma, brain oedema, and death. Bio-
chemical abnormalities include hyperammonemia, elevated
plasma levels of glutamine, decreased level of citrulline and oro-
tic aciduria [8]. Individuals who have mild molecular urea-cycle
disorders can lead a relatively normal life until a severe environ-
mental stress, such as infections, surgery, pregnancy or high-dose
steroids trigger a hyperammonemic crisis [5–7]. The prompt rec-
ognition and treatment of such crises are essential for a good
outcome.
We describe a 47-year-old man with previously undiagnosed
OTC deﬁciency, who acquired hyperammonemic encephalopathy
after starting the low-carbohydrates, high-protein, and high-fat
Atkins diet. Molecular genetic investigation revealed a novel mis-
sense mutation (Ile159Met) in the OTC gene in the patient and in
several asymptomatic members of his three-generation family.Case report
A 47-year-old Ashkenazi Jew presented himself to the emergency
room of our tertiary medical centre because of vomiting, inter-
mittent lethargy, and increasing somnolence of 3 days’ duration.
There were no other co-morbidities. He was transferred to the
Neurology Department for further evaluation. Past medical his-
tory was unremarkable for chronic conditions. He had never
had an episode of altered mental status. Initial laboratory work-
up revealed a normal complete blood count, and the renal panel
showed a normal creatinine level without an anion gap. Serum
liver enzyme levels were slightly increased with normal synthetic
liver function tests (serum albumin and INR) (Table 1). The
patient was slightly overweight (BMI 28.2 kg/m2) but there were
no other known risk factors for chronic liver disease. A history of
ethanol consumption was excluded and a routine laboratory
examination that was performed to exclude other causes of liver
disease, such as viral hepatitis B or C, or autoimmune hepatitis
and Wilson’s disease were negative. Abdominal ultrasound and
Doppler revealed that both liver and spleen had a normal size
and texture, as well as no evidence for fatty liver, portal
hypertension or portal-systemic shunting. Urinalysis was
non-contributory. Brain computed tomography (CT), magnetic
resonance imaging, and electroencephalography (EEG) revealed
no pathology. Findings on lumbar puncture (cells, protein, glu-
cose and chloride levels) were within normal range.
Over the next few days, the patient became increasingly dis-
oriented and aggressive. On the fourth day, seizures developed,
and one dose of sodium valproate was administered. Repeated
EEG performed within 4 days from the previous one showed gen-
eralized slowing with presence of triphasic waves and the
appearance of delta waves suggesting a metabolic insult. Serum
ammonia, tested for the ﬁrst time, measured 541 mcg/dl (normal
range, 20–82 mcg/dl), consistent with hyperammonemic enceph-
alopathy. Repeated CT scan showed cerebral oedema.
Following the patient’s further neurological deterioration with
coma, mechanical ventilation was started, and the patient was
transferred to the Intensive Care Unit. At that point, a family
member informed us that in an attempt to lose weight, the
patient had started the low-carbohydrates (20 g daily), and
unlimited high-protein, high-fat Atkins diet 3 days prior to
admission. This information, combined with the ﬁndings of
hyperammonemia, raised the possibility of an inborn error of
metabolism. Serum amino acid proﬁle revealed a glutamine levelJournal of Hepatology 201of 1381 lmol/l (reference range, 413–690 lmol/l) and a serum
citrulline level of 14 lmol/l (reference range, 10–50 lmol/l).
Analysis of urinary organic acids revealed increased secretion of
orotic acid and uracil. Acylcarnitine proﬁle was normal. The
hyperammonemia together with the elevated serum glutamine
and urinary orotic acid levels and low citralline level suggested
the diagnosis of OTC deﬁciency.
The patient was treated with hemodialysis to remove the
ammonia from the circulation combined with the administration
of L-arginine and sodium phenylbutyrate and an intravenous
hypercaloric regimen of 20% glucose and 20% intralipid prepara-
tion. To prevent further endogenous protein catabolism, dietary
protein was eliminated for 24 h, and then a low-protein diet
was introduced. The patient responded remarkably to treatment
within 24 h. Following two cycles of hemodialysis, serum ammo-
nia level normalized. The patient became more alert, and within
the next few days, his mental status recovered.
On a follow-up visit a few months later, the patient appeared
healthy. He had returned to his previous active life while main-
taining a minimal, limited-protein diet. His repeated serum
ammonia level was 50 mcg/dl.
Polymerase chain reaction (PCR) ampliﬁcation and DNA
sequencing of the OTC gene in the patient (Fig. 1, III-3) using a
multiplex PCR protocol [9] revealed a novel hemizygous muta-
tion in exon 5 (c.477T>G), leading to an isoleucine-to-methionine
substitution in codon 159 (Ile159Met). Further testing in other
family members (Fig. 1) yielded the same missense mutation.
However, the mutation was not detected in any of 89 unrelated
Ashkenazi Jewish and 50 unrelated Europeans subjects tested.Discussion
The present report is of great clinical importance because
late-onset presentations of urea-cycle disorders often go unrec-
ognized and may be life-threatening [5–7]. Early symptoms of
confusion or neurological manifestations such as seizures may
be followed by cerebral oedema and herniation. Prompt recogni-
tion can prevent such a fatal outcome because effective treatment0 vol. 52 j 292–295 293
Fig. 1. Pedigree of a four-generation family with OTC deﬁciency caused by
Ile159Met mutation.
Case Reportincluding hemodialysis, provision of adequate calories to prevent
further catabolism, protein elimination for 24 h followed by pro-
tein restriction and ammonia scavenging medications could
effectively normalize plasma ammonia level and result in full
recovery [10–12].
The diagnosis of urea-cycle disorder is based on clinical, bio-
chemical, and molecular data. Clinical symptoms are often non-
speciﬁc and include headache, nausea, vomiting, behavioral
changes suggesting a psychiatric disorder, seizures, and coma.
Our patient posed a considerable diagnostic dilemma because
he was asymptomatic until the age of 47 years, when he pre-
sented with vomiting and behavioral changes and then lapsed
into a coma. Biochemically, a serum ammonia level of 150 mcg/
dl or higher associated with a normal anion gap and a normal
serum glucose concentration is a strong indication for the pres-
ence of a urea-cycle disorder [5]. In the present case, our suspi-
cion of a urea-cycle disorder was raised by ﬁndings of an
elevated serum ammonia level combined with only a mild
increase in serum transaminase levels and the absence of any fea-
tures suggesting acute liver failure (normal synthetic liver func-
tion tests). Individuals with a mild molecular urea-cycle defect
can lead a normal life until a severe environmental stress triggers
a hyperammonemic crisis. Episodes of hyperammonemic
encephalopathy are usually preceded by states of increased
catabolism, such as infections, surgery, or pregnancy. Interest-
ingly, high-dose steroids have been implicated in unmasking
urea-cycle disorders in adults [5–7].
This is the ﬁrst report in which the Atkins diet was associated
with adult onset of a urea-cycle disorder. Atkins diet involves
high-fat/protein diet and restriction of carbohydrates (20 g daily),
thus, switching the body’s metabolism from burning glucose as
fuel to burning stored body fat (ketosis). The diet claims to be
effective at producing weight loss despite ad libitum consump-
tion of fatty meat, butter, and other high-fat dairy products.
According to Dr. Atkins who created this diet, it produces a met-
abolic advantage in which the body burns more calories, overall,
than on normal diets. The patient had been symptom-free so long
as he was on a regular protein diet and had not been exposed to
severe environmental stress. The high dietary protein induced
hyperammonemic encephalopathy, revealing the underlying294 Journal of Hepatology 201mild OTC deﬁciency. Considering the popularity of this diet and
the accompanying Atkins food products in the wake of the cur-
rent obesity epidemic, it is rather surprising that no such case
has been described before. It is possible that some individuals
with mild OTC deﬁciency who tried the diet quit because of non-
speciﬁc symptoms (headache, nausea, vomiting), thereby pre-
venting further deterioration. Hence, an increased awareness of
the possible existence of an inborn error of metabolism in the
urea cycle is essential since its prompt recognition is critical for
an effective management.
The goal of treatment of urea-cycle disorders is to reduce the
serum ammonia level as quickly as possible to prevent brain
injury or even death [2,10,12]. The regimen includes hemodialy-
sis, provision of non-protein high-calorie diet (to prevent further
catabolism), protein elimination for 24 h followed by protein
restriction, and administration of ammonia scavenging medica-
tions (sodium phenylacetate, sodium benzoate, arginine hydro-
chloride). Our patient was also administered valproic acid
following seizures; prior to the diagnosis of the OTC defect, its
administration could have worsened his condition. It is notewor-
thy that valproic acid is the most widely recognized agent with
known direct toxic-inhibitory effects on urea-cycle enzymes
[13]. Valproic acid impairs the transformation of carbamyl phos-
phate and ornithine into citrulline directly by inhibiting the
enzyme carbamyl phosphate synthetase. Valproate-induced
hyperammonemic encephalopathy is a rare adverse event; symp-
toms appeared either a few days after initiation of valproate ther-
apy, or after several months or years. All patients recovered after
discontinuation of valproate [13].
More than 340 mutations in the OTC gene have been iden-
tiﬁed, most of them speciﬁc to individual families [3,14].
Patients with a partial enzyme deﬁciency have ‘‘mild”, usually
single-base, mutations. The wide phenotypic heterogeneity of
OTC deﬁciency, even among patients with the same mutation
and within the same family, is poorly understood and seems
to be due to a combination of genetic and environmental fac-
tors [14].
In the present case, the Ile159Met mutation was detected in
the patient (III-3) and in his asymptomatic 42-year-old sister
(III-1), his 37-year-old brother (III-2), and their 60-year-old
asymptomatic mother (II-1) (Fig. 1). One of the fourth-generation
nonidentical twins (IV-6), aged 10 years, was an obligatory car-
rier (because her father carried the mutation), and reportedly
had had recurrent episodes of vomiting of unknown cause since
infancy. At the same time, an aunt of the index patient (II-2), also
a carrier of the mutation, had been successfully practicing the
same Atkins diet for months and remained asymptomatic. The
variability of clinical presentation of a given OTC mutation in
female patients is partially explained by variable mosaic X chro-
mosome inactivation.
Ile159Met is a novel mutation. However, there is one case
in the literature of an amino acid substitution at the same site
in exon 5 (Ile159Thr, c.476T>C) which was also associated with
late-onset symptoms of OTC deﬁciency [15]. As more novel
mutations are found and reported, with corresponding clinical
and biochemical information, we will acquire a better under-
standing of the genotype–phenotype correlation in OTC deﬁ-
ciency and of the functional domains of the OTC protein that
are critical for normal enzyme activity [14]. Most of the muta-
tions still await conﬁrmation of their deleterious effect by
expression studies. Recent reports on the tertiary structure of0 vol. 52 j 292–295
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the human OTC protein helped to elucidate the regions of the
gene that are involved in OTC function and assembly, making it
easier for clinicians to predict whether a particular mutation is
likely to be detrimental and what phenotype should be
expected. The majority of mutations in patients with a neona-
tal presentation involve amino acid residues located within the
interior region of the protein or at the active site, whereas
most of those in patients with late-onset disease involve amino
acids that are remote from the active site or located on the
surface of the protein [4,8,14,16]. Using this information, clini-
cians can make earlier decisions on the need for invasive ther-
apy (e.g., liver transplantation) or conservative therapy (diet
and medications). Additionally, mutation analysis in OTC deﬁ-
ciency, as depicted in the present kindred, allows for accurate
and speciﬁc carrier testing and prenatal diagnosis in families
with affected members [14].
In conclusion, individuals with a mild urea-cycle defect can
lead a relatively normal life until an environmental stress, such
as protein loading due to the Atkins diet, triggers a hyperammo-
nemic crisis. Prompt recognition and treatment of the disorder
are essential to good patient outcome. Measurements of serum
ammonia level must be part of the basic work-up in all patients,
of any age, presenting with encephalopathy of unknown origin
even in the absence of liver dysfunction.
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